Specimen collection for induced pluripotent stem cell research: Harmonizing the approach to informed consent

Stem Cells Translational Medicine

Volumn 1, Issue 5, 2012, Pages 409-421

  Lowenthal, Justin ^a   Lipnick, Scott ^b,c   Rao, Mahendra ^b,d   Hull, Sara Chandros ^a,e  

^a CLINICAL CENTER   (United States)

^b Center for Neuroscience and Regenerative Medicine   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

^e NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

Author keywords

Clinical translation; Ethics; Induced pluripotent stem cells; iPS

Indexed keywords

ARTICLE; DUTY TO RECONTACT; ETHICS; HUMAN; INFORMED CONSENT; INTERPERSONAL COMMUNICATION; NATIONAL HEALTH ORGANIZATION; PARTICIPATORY MANAGEMENT; PLURIPOTENT STEM CELL; PRODUCT DEVELOPMENT; PROFESSIONAL SECRECY; REASSURANCE; REGENERATIVE MEDICINE; STEM CELL RESEARCH; STEM CELL TRANSPLANTATION; CYTOLOGY; LABORATORY DIAGNOSIS; LEGAL ASPECT; PRACTICE GUIDELINE; STANDARD;

HUMANS; INDUCED PLURIPOTENT STEM CELLS; INFORMED CONSENT; PRACTICE GUIDELINES AS TOPIC; REGENERATIVE MEDICINE; SPECIMEN HANDLING; STEM CELL RESEARCH;

EID: 84871509371     PISSN: 21576564     EISSN: 21576580     Source Type: Journal    
DOI: 10.5966/sctm.2012-0029     Document Type: Article

References (141)

1. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006;126:663-676.
2. Zhang X, De Los Angeles A, Zhang J. The art of human induced pluripotent stem cells: The past, the present and the future. Open Stem Cell J 2010;2:2-7.
3. Takahashi K, Tanabe K, Ohnuki M et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007;131:861-872.
4. Yu J, Vodyanik MA, Smuga-Otto K et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007;318: 1917-1920.
5. Gutierrez-Aranda I, Ramos-Mejia V, Bueno C et al. Human induced pluripotent stem cells develop teratoma more efficiently and faster than human embryonic stem cells regardless the site of injection. STEM CELLS 2010; 28:1568-1570.
6. Okita K, Ichisaka T, Yamanaka S. Generation of germline-competent induced pluripotent stem cells. Nature 2007;448:313-317.
7. Ma J, Guo L, Fiene SJ et al. High purity human-induced pluripotent stem cell-derived cardiomyocytes: Electrophysiological properties of action potentials and ionic currents. Am J Physiol Heart Circ Physiol 2011;301: H2006-H2017.
8. Bharti K, Miller SS, Arnheiter H. The new paradigm: Retinal pigment epithelium cells generated from embryonic or induced pluripotent stem cells. Pigment Cell Melanoma Res 2011;24:21-34.
9. Phanstiel DH, Brumbaugh J, Wenger CD et al. Proteomic and phosphoproteomic comparison of human ES and iPS cells. Nat Methods 2011;8:821-827.
10. Stadtfeld M, Nagaya M, Utikal J et al. Induced pluripotent stem cells generated without viral integration. Science 2008;322:945-949.
11. Yu J, Hu K, Smuga-Otto K et al. Human induced pluripotent stem cells free of vector and transgene. Science 2009;324:797-801.
12. Warren L, Manos PD, Ahfeldt T et al. Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell 2010;7:618-630.
13. Giorgetti A, Montserrat N, Rodriguez-Piza I et al. Generation of induced pluripotent stem cells from human cord blood cells with only two factors: Oct4 and Sox2. Nat Protoc 2010;5:811-820.
14. Anokye-Danso F, Trivedi CM, Juhr D et al. Highly efficient miRNA-mediated reprogramming of mouse and human somatic cells to pluripotency. Cell Stem Cell 2011;8:376-388.
15. Feng B, Ng JH, Heng JC et al. Molecules that promote or enhance reprogramming of somatic cells to induced pluripotent stem cells. Cell Stem Cell 2009;4:301-312.
16. Ho R, Chronis C, Plath K. Mechanistic insights into reprogramming to induced pluripotency. J Cell Physiol 2011;226:868-878.
17. Li W, Ding S. Small molecules that modulate embryonic stem cell fate and somatic cell reprogramming. Trends Pharmacol Sci 2010; 31:36-45.
18. Li W, Jiang K, Ding S. A chemical approach to controlling cell fate and function. STEM CELLS 2012;30:61-68.
19. Burridge PW, Thompson S, Millrod MA et al. A universal system for highly efficient cardiac differentiation of human induced pluripotent stem cells that eliminates interline variability. PLoS One 2011;6:e18293.
20. Hanna J, Saha K, Pando B et al. Direct cell reprogramming is a stochastic process amenable to acceleration. Nature 2009;462:595-601.
21. Zwi-Dantsis L, Mizrahi I, Arbel G et al. Scalable production of cardiomyocytes derived from c-Myc free induced pluripotent stem cells. Tissue Eng Part A 2011;17:1027-1037.
22. Narsinh KH, Wu JC. Gene correction in human embryonic and induced pluripotent stem cells: Promises and challenges ahead. Mol Ther 2010;18:1061-1063.
23. Rao M, Ahrlund-Richter L, Kaufman DS. Concise review: Cord blood banking, transplantation and induced pluripotent stem cell: Success and opportunities. STEM CELLS 2012;30:55-60.
24. Rajesh D, Dickerson SJ, Yu J et al. Human lymphoblastoid B-cell lines reprogrammed to EBV-free induced pluripotent stem cells. Blood 2011;118:1797-1800.
25. Haase A, Olmer R, Schwanke K et al. Generation of induced pluripotent stem cells from human cord blood. Cell Stem Cell 2009;5:434-441.
26. Tan KY, Eminli S, Hettmer S et al. Efficient generation of iPS cells from skeletal muscle stem cells. PLoS One 2011;6:e26406.
27. Mei Y, Saha K, Bogatyrev SR et al. Combinatorial development of biomaterials for clonal growth of human pluripotent stem cells. Nat Mater 2010;9:768-778.
28. Saha K, Mei Y, Reisterer CM et al. Surface-engineered substrates for improved human pluripotent stem cell culture under fully defined conditions. Proc Natl Acad Sci USA 2011;108:18714-18719.
29. Efe JA, Yuan X, Jiang K et al. Development unchained: How cellular reprogramming is redefining our view of cell fate and identity. Sci Prog 2011;94:298-322.
30. Ieda M, Fu JD, Delgado-Olguin P et al. Direct reprogramming of fibroblasts into functional cardiomyocytes by defined factors. Cell 2010;142:375-386.
31. Kim J, Efe JA, Zhu S et al. Direct reprogramming of mouse fibroblasts to neural progenitors. Proc Natl Acad Sci USA 2011;108: 7838-7843.
32. Dyson SC, Barker RA. Cell-based therapies for Parkinson's disease. Expert Rev Neurother 2011;11:831-844.
33. Galach M, Utikal J. From skin to the treatment of diseases-the possibilities of iPS cell research in dermatology. Exp Dermatol 2011; 20:523-528.
34. Rhee YH, Ko JY, Chang MY et al. Protein-based human iPS cells efficiently generate functional dopamine neurons and can treat a rat model of Parkinson disease. J Clin Invest 2011;121:2326-2335.
35. Vaccarino FM, Stevens HE, Kocabas A et al. Induced pluripotent stem cells: A new tool to confront the challenge of neuropsychiatric disorders. Neuropharmacology 2011;60: 1355-1363.
36. Wetsel RA, Wang D, Calame DG. Therapeutic potential of lung epithelial progenitor cells derived from embryonic and induced pluripotent stem cells. Annu Rev Med 2011;62: 95-105.
37. Cai W, Zhang Y, Kamp TJ. Imaging of induced pluripotent stem cells: From cellular reprogramming to transplantation. Am J Nucl Med Mol Imaging 2011;1:18-28.
38. Itzhaki I, Maizels L, Huber I et al. Modelling the long QT syndrome with induced pluripotent stem cells. Nature 2011;471:225-229.
39. Park IH, Arora N, Huo H et al. Diseasespecific induced pluripotent stem cells. Cell 2008;134:877-886.
40. Saha K, Jaenisch R. Technical challenges in using human induced pluripotent stem cells to model disease. Cell Stem Cell 2009;5:584-595.
41. Saha K, Hurlbut JB. Disease modeling using pluripotent stem cells: Making sense of disease from bench to bedside. Swiss Med Wkly 2011;141:w13144.
42. Urbach A, Bar-Nur O, Daley GQ et al. Differential modeling of fragile X syndrome by human embryonic stem cells and induced pluripotent stem cells. Cell Stem Cell 2010;6:407-411.
43. Inoue H, Yamanaka S. The use of induced pluripotent stem cells in drug development. Clin Pharmacol Ther 2011;89:655-661.
44. Sun N, Longaker MT, Wu JC. Human iPS cell-based therapy: Considerations before clinical applications. Cell Cycle 2010;9:880-885.
45. Power C, Rasko JE. Promises and challenges of stem cell research for regenerative medicine. Ann Intern Med 2011;155:706-713, W217.
46. Liras A. Induced human pluripotent stem cells and advanced therapies: Future perspectives for the treatment of haemophilia? Thromb Res 2011;128:8-13.
47. Parker KK, Ingber DE. Extracellular matrix, mechanotransduction and structural hierarchies in heart tissue engineering. Philos Trans R Soc Lond B Biol Sci 2007;362:1267-1279.
48. Tucker BA, Park IH, Qi SD et al. Transplantation of adult mouse iPS cell-derived photoreceptor precursors restores retinal structure and function in degenerative mice. PLoS One 2011;6:e18992.
49. Yusa K, Rashid ST, Strick-Marchand H et al. Targeted gene correction of alpha1-antitrypsin deficiency in induced pluripotent stem cells. Nature 2011;478:391-394.
50. Boland MJ, Hazen JL, Nazor KL et al. Adult mice generated from induced pluripotent stem cells. Nature 2009;461:91-94.
51. Yao L, Yu X, Hui N et al. Application of iPS in assisted reproductive technology: Sperm from somatic cells? Stem Cell Rev 2011;7:714-721.
52. Gore A, Li Z, Fung HL et al. Somatic coding mutations in human induced pluripotent stem cells. Nature 2011;471:63-67.
53. Hussein SM, Batada NN, Vuoristo S et al. Copy number variation and selection during reprogramming to pluripotency. Nature 2011; 471:58-62.
54. Laurent LC, Ulitsky I, Slavin I et al. Dynamic changes in the copy number of pluripotency and cell proliferation genes in human ESCs and iPSCs during reprogramming and time in culture. Cell Stem Cell 2011;8:106-118.
55. Mayshar Y, Ben-David U, Lavon N et al. Identification and classification of chromo-somal aberrations in human induced pluripotent stem cells. Cell Stem Cell 2010;7:521-531.
56. Kim K, Doi A, Wen B et al. Epigenetic memory in induced pluripotent stem cells. Nature 2010;467:285-290.
57. Lister R, Pelizzola M, Kida YS et al. Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells. Nature 2011;471:68-73.
58. Ohm JE, Mali P, Van Neste L et al. Cancer-related epigenome changes associated with reprogramming to induced pluripotent stem cells. Cancer Res 2010;70:7662-7673.
59. Ben-David U, Benvenisty N. The tumori-genicity of human embryonic and induced pluripotent stem cells. Nat Rev Cancer 2011;11: 268-277.
60. Apostolou E, Hochedlinger K. Stem cells: iPS cells under attack. Nature 2011;474:165-166.
61. Pera MF. Stem cells: The dark side of induced pluripotency. Nature 2011;471:46-47.
62. Zhao T, Zhang ZN, Rong Z et al. Immunogenicity of induced pluripotent stem cells. Nature 2011;474:212-215.
63. Crook JM, Peura TT, Kravets L et al. The generation of six clinical-grade human embryonic stem cell lines. Cell Stem Cell 2007;1:490-494.
64. Ng VY, Choo ABH. iPS and ES cells: Do both roads lead to Rome? Open Stem Cell J 2010;2:8-17.
65. Rao MS, Collins FS. Steering a new course for stem cell research: NIH's intramural center for regenerative medicine. STEM CELLS TRANSLATIONAL MEDICINE 2012;1:15-17.
66. Lehrman S. Undifferentiated ethics. Sci Am 2010;303:18, 20.
67. Aalto-Setälä K, Conklin BR, Lo B. Obtaining consent for future research with induced pluripotent cells: Opportunities and challenges. PLoS Biol 2009;7:e42.
68. Shineha R, Kawakami M, Kawakami K et al. Familiarity and prudence of the Japanese public with research into induced pluripotent stem cells, and their desire for its proper regulation. Stem Cell Rev 2010;6:1-7.
69. Skloot R. The Immortal Life of Henrietta Lacks. 1st pbk. ed. New York: Broadway Paperbacks, 2011.
70. Hull SC, Gooding H, Klein AP et al. Genetic research involving human biological materials: A need to tailor current consent forms. IRB 2004;26:1-7.
71. White MT, Gamm J. Informed consent for research on stored blood and tissue samples: A survey of institutional review board practices. Account Res 2002;9:1-16.
72. Streiffer R. Informed consent and federal funding for stem cell research. Hastings Cent Rep 2008;38:40-47.
73. Baker M. Consent issues restrict stemcell use. Nature 2008;454:556.
74. Dolgin E. NIH accused of being overly literal on stem cell approvals. Nat Med 2012;18: 325.
75. Scott CT, Caulfield T, Borgelt E et al. Personal medicine-the new banking crisis. Nat Biotechnol 2012;30:141-147.
76. National Bioethics Advisory Commission. Research Involving Human Biological Materials: Ethical Issues and Policy Guidance. August 1999. Available at http://bioethics.georgetown.edu/nbac/hbm_exec.pdf. Accessed January 22, 2012.
77. Wendler D. One-time general consent for research on biological samples. BMJ 2006; 332:544-547.
78. Hansson MG, Dillner J, Bartram CR et al. Should donors be allowed to give broad consent to future biobank research? Lancet Oncol 2006;7:266-269.
79. Emanuel EJ, Menikoff J. Reforming the regulations governing research with human subjects. N Engl J Med 2011;365:1145-1150.
80. Chen DT, Rosenstein DL, Muthappan P et al. Research with stored biological samples: What do research participants want? Arch Intern Med 2005;165:652-655.
81. Miller FG, Wertheimer A. Facing up to paternalism in research ethics. Hastings Cent Rep 2007;37:24-34.
82. Taube SE, Barr P, LiVolsi V et al. Ensuring the availability of specimens for research. Breast J 1998;4:391-395.
83. Emanuel EJ, Wendler D, Grady C. What makes clinical research ethical? JAMA 2000; 283:2701-2711.
84. Isasi R, Knoppers BM, Lomax G. Sustained interaction: The new normal for stem cell repositories? Regen Med 2011;6:783-792.
85. Rao M, Condic ML. Alternative sources of pluripotent stem cells: Scientific solutions to an ethical dilemma. Stem Cells Dev 2008; 17:1-10.
86. President's Council on Bioethics. White Paper: Alternative Source of Pluripotent Stem Cells. May 2005. Available at http://bioethics.georgetown.edu/pcbe/reports/white_paper/index.html. Accessed January 22, 2012.
87. Krauthammer C. Stem cell vindication. Washington Post, November 30, 2007. Available at http://www.washingtonpost.com/wp-dyn/content/article/2007/11/29/AR2007112901878.html. Accessed February 15, 2012.
88. Condic ML, Rao M. Alternative sources of pluripotent stem cells: Ethical and scientific issues revisited. Stem Cells Dev 2010;19:1121-1129.
89. Suaudeau J. From embryonic stem cells to iPS-an ethical perspective. Cell Prolif 2011; 44(suppl 1):70-84.
90. Power C, Rasko JE. Will cell reprogramming resolve the embryonic stem cell controversy? A narrative review. Ann Intern Med 2011;155:114-121.
91. Crook JM. Human iPS cells: Science and ethics. Open Stem Cell J 2010;2:1.
92. Watt JC, Kobayashi NR. The bioethics of human pluripotent stem cells: Will induced pluripotent stem cells end the debate? Open Stem Cell J 2010;2:18-24.
93. Brown MT. Moral complicity in induced pluripotent stem cell research. Kennedy Inst Ethic J 2009;19:1-22.
94. Denker HW. Potentiality of embryonic stem cells: An ethical problem even with alternative stem cell sources. J Med Ethics 2006;32: 665-671.
95. Devolder K. Complicity in stem cell research: The case of induced pluripotent stem cells. Hum Reprod 2010;25:2175-2180.
96. Hyun I. Stem cells from skin cells: The ethical questions. Hastings Cent Rep 2008;38: 20-22.
97. Hyun I, Hochedlinger K, Jaenisch R et al. New advances in iPS cell research do not obviate the need for human embryonic stem cells. Cell Stem Cell 2007;1:367-368.
98. Testa G, Borghese L, Steinbeck JA et al. Breakdown of the potentiality principle and its impact on global stem cell research. Cell Stem Cell 2007;1:153-156.
99. Neri D. The race toward 'ethically universally acceptable' human pluripotent (embryonic-like) stem cells: Only a problem of sources? Bioethics 2011;25:260-266.
100. Mathews DJ, Donovan PJ, Harris J et al. Pluripotent stem cell-derived gametes: Truth and (potential) consequences. Cell Stem Cell 2009;5:11-14.
101. Ramalho-Santos J. Human procreation in unchartered territory: New twists in ethical discussions. Hum Reprod 2011;26:1284-1287.
102. Lo B, Parham L, Alvarez-Buylla A et al. Cloning mice and men: Prohibiting the use of iPS cells for human reproductive cloning. Cell Stem Cell 2010;6:16-20.
103. International Society for Stem Cell Research. Guidelines for the Conduct of Human Embryonic Stem Cell Research. 2006. Available at http://www.isscr.org/guidelines/ISSCRhESCguidelines2006.pdf. Accessed February 24, 2012.
104. National Research Council and Institute of Medicine. 2008 Amendments to the National Academies' Guidelines for Human Embryonic Stem Cell Research. National Academy Press. Available at http://www.nap.edu/catalog.php?record_id12260. Accessed February 24, 2012.
105. Mathews DJ, Graff GD, Saha K et al. Access to stem cells and data: Persons, property rights, and scientific progress. Science 2011; 331:725-727.
106. Lo B, Parham L. Ethical issues in stem cell research. Endocr Rev 2009;30:204-213.
107. Caulfield T, Scott C, Hyun I et al. Stem cell research policy and iPS cells. Nat Methods 2010;7:28-33.
108. Zarzeczny A, Scott C, Hyun I et al. iPS cells: Mapping the policy issues. Cell 2009;139: 1032-1037.
109. Luong MX, Auerbach J, Crook JM et al. A call for standardized naming and reporting of human ESC and iPSC lines. Cell Stem Cell 2011; 8:357-359.
110. U.S. Food and Drug Administration. A Guide to Informed Consent-Information Sheet. 21.CFR. 50. Available at http://www.fda.gov/RegulatoryInformation/Guidances/ucm126431.htm. Accessed February 24, 2012.
111. U.S. Food and Drug Administration. 21.CFR. 1270. Available at http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart 1270. Accessed February 24, 2012.
112. U.S. Food and Drug Administration. 21.CFR. 1271. Available at http://www. accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart 1271. Accessed February 24, 2012.
113. Koleva G. Stem cells and the lawsuit that may shape our medical future. Forbes. February 10, 2012. Available at http://www.forbes.com/sites/gerganakoleva/2012/02/10/stem-cells-and-the-lawsuit-that-may-shape-our-medical-future. Accessed February 15, 2012.
114. Hyun I. Allowing innovative stem cell-based therapies outside of clinical trials: Ethical and policy challenges. J Law Med Ethics 2010; 38:277-285.
115. Regulators must step up stem cell over-sight. Nat Med 2010;16:492.
116. Hyun I. The bioethics of stem cell research and therapy. J Clin Invest 2010;120:71-75.
117. Hyun I. The bioethics of iPS cell-based drug discovery. Clin Pharmacol Ther 2011;89: 646-647.
118. Daley GQ, Ahrlund Richter L, Auerbach JM et al. Ethics. The ISSCR guidelines for human embryonic stem cell research. Science 2007; 315:603-604.
119. Hyun I, Lindvall O, Ahrlund-Richter L et al. New ISSCR guidelines underscore major principles for responsible translational stem cell research. Cell Stem Cell 2008;3:607-609.
120. International Society for Stem Cell Research. ISSCR Patient Guidelines for the Clinical Translation of Stem Cells. December 23, 2008. Available http://www.isscr.org/ GuidelinesforClinicalTranslation/2480.htm. Accessed January 12, 2012.
121. The International Stem Cell Banking Initiative. Consensus guidance for banking and supply of human embryonic stem cell lines for research purposes. Stem Cell Rev Rep 2009;5: 301-314.
122. National Research Council and Institute of Medicine. Final Report of the National Academies' Human Embryonic Stem Cell Research Advisory Committee and 2010 Amendments to The National Academies' Guidelines for Human Embryonic Stem Cell Research. National Academy Press. Available at http://www.nap.edu/catalog.php?record_id 12923. Accessed February 24, 2012.
123. U.S. National Institutes of Health. National Cancer Institute Office of Biorepositories and Biospecimen Research. 2011 Revised NCI Best Practices for Biospecimen Resources. Available at http://biospecimens.cancer.gov/ practices/2011bp.asp. Accessed March 5, 2012.
124. California Institute for Regenerative Medicine. CIRM MES Regulations Title 17 California Code of Regulations Section 100010-100110.2006. Available at http://www.cirm.ca.gov/files/PDFs/Standards/Reformatted_MES_Regs.pdf. Accessed February 12, 2012.
125. California Institute for Regenerative Medicine. Summary and Recommendations of the CIRM Human iPS Cell Banking Workshop. November 17-18, 2010. Available at http://www.cirm.ca.gov/MeetingReports. Accessed February 12, 2012.
126. U.S. Department of Health and Human Services. Protection of Human Subjects. 45.CFR. 46. Available at http://www.hhs.gov/ohrp/humansubjects/guidance/45cfr46.htm. Accessed February 24, 2012.
127. Hull SC, Sharp RR, Botkin JR et al. Patients' views on identifiability of samples and informed consent for genetic research. Am J Bioeth 2008;8:62-70.
128. Casebriefs. Moore v. Regents of the University of California. Available at http://www.casebriefs.com/blog/law/property/property-law-keyed-to-cribbet/non-traditional-objects-and-classifications-of-property/moore-v-regents-of-the-university-of-california-2. Accessed February 15, 2012.
129. Beskow LM, Friedman JY, Hardy NC et al. Simplifying informed consent for biorepositories: Stakeholder perspectives. Genet Med 2010;12:567-572.
130. Cressey D. Informed consent on trial. Nature 2012;482:16.
131. Schaefer GO, Wertheimer A. The right to withdraw from research. Kennedy Inst Ethics J 2010;20:329-352.
132. Mello MM, Wolf LE. The Havasupai Indian tribe case-lessons for research involving stored biologic samples. N Engl J Med 2010; 363:204-207.
133. Ludman EJ, Fullerton SM, Spangler L et al. Glad you asked: Participants' opinions of re-consent for dbGap data submission. J Empir Res Hum Res Ethics 2010;5:9-16.
134. Goldenberg AJ, Hull SC, Botkin JR et al. Pediatric biobanks: Approaching informed consent for continuing research after children grow up. J Pediatr 2009;155:578-583.
135. Hens K, Levesque E, Dierickx K. Children and biobanks: A review of the ethical and legal discussion. Hum Genet 2011;130: 403-413.
136. Bahadur G, Morrison M. Patenting human pluripotent cells: Balancing commercial, academic and ethical interests. Hum Reprod 2010;25:14-21.
137. Caulfield T, Rachul C. Science spin: iPS cell research in the news. Clin Pharmacol Ther 2011;89:644-646.
138. King NM, Henderson GE, Churchill LR et al. Consent forms and the therapeutic misconception: The example of gene transfer research. IRB 2005;27:1-8.
139. Scott CT, DeRouen MC, Crawley LM. The language of hope: Therapeutic intent in stem-cell clinical trials. AJOB Primary Res 2010;1:4-11.
140. U.S. National Institutes of Health. National Institutes of Health Guidelines on Human Stem Cell Research. Available at http://stemcells.nih.gov/policy/2009guidelines.htm. Accessed January 22, 2012.
141. International Society for Stem Cell Research. ISSCR Patient Handbook on Stem Cell Therapies. December 23, 2008. Available at http://www.isscr.org/The_Patient_Handbook.htm. Accessed January 12, 2012.